Sustained Release GLP-1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinson’s Disease

[Image: see text] GLP-1 agonists have become increasingly interesting as a new Parkinson’s disease (PD) clinical treatment strategy. Additional preclinical studies are important to validate this approach and define the disease stage when they are most effective. We hence characterized the efficacy o...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:ACS Pharmacol Transl Sci
Huvudupphovsmän: Wang, Vicki, Kuo, Tung-Tai, Huang, Eagle Yi-Kung, Ma, Kuo-Hsing, Chou, Yu-Ching, Fu, Zhao-Yang, Lai, Li-Wen, Jung, Jin, Choi, Hoi-II, Choi, Doo-Sup, Li, Yazhou, Olson, Lars, Greig, Nigel H., Hoffer, Barry J., Chen, Yuan-Hao
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Chemical Society 2021
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC8033754/
https://ncbi.nlm.nih.gov/pubmed/33860208
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsptsci.1c00013
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk